U.S. biopharma Incyte has inaugurated its new European headquarters in Morges on July 6th. In parallel, the company is investing 100 million Swiss francs in a production facility in Yverdon-les-Bains that will be fully operational in 2021.
“The opening of our new European headquarters will have a positive impact on our employees and foster collaboration across Europe,” said Jonathan Dickinson, Executive Vice President and General Manager Europe at Incyte.
The new facility, named Campus Léman, will soon house more than 150 employees from the company’s global and regional regulatory, clinical development, commercial, medical affairs and technical operations groups, as well as team members across other support functions. The campus extends over 11,600m2 and includes a restaurant and a garden, which will be partially accessible to the public.
Incyte focuses on the discovery, development and commercialization of novel medicines in oncology, inflammation and autoimmunity. Founded in 2002 in Wilmington, Delaware, today the company employs approximately 1,500 people in the U.S., Europe and Japan. Following the acquisition of ARIAD Pharmaceuticals’ European operations in 2016, Incyte announced plans to further expand its Swiss operations via the establishment of a 60,000m2 production plant at the Y-PARC Science and Technology Park in Yverdon-les-Bains. This site is expected to be fully operational in 2021.
